Orthocell has appointed its second distributor in Canada. The appointment completes national coverage across the US$75 million Canadian market, ensuring access for patients and healthcare providers nationwide.
First Remplir™ Surgical Case Completed in Hong Kong
Orthocell has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences
Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Orthocell Appoints Exclusive Remplir™ Distributor for Hong Kong
Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.
Orthocell secures global distribution rights to innovative bone regeneration technology
Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone™.
$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Quarterly Report – period ended 30 September 2025
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell Announces Record Revenue of $3m for September Quarter
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market
Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.
STOCKHEAD | Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market
Orthocell was featured in a Stockhead article by leading biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market.”
The article explores our global expansion, including the rapid rollout of Remplir in the US following FDA clearance, new international markets such as Canada and Asia, and emerging opportunities in prostate surgery. It also highlights the Company’s strong financial position as we scale globally.
Here’s an excerpt:
“Van Der Wielen notes Orthocell’s revenue has grown at an average annual compound rate of 34% over the past three years. The company is “not too far from heading to profit” as US revenues flow in.
“We are at an inflexion point,” Van Der Wielen says. “We expect to see revenue rates sustainably increase. We are very much focused on the US and couldn’t be happier with the progress and the quality of people we already have employed.”